4. Status Epilepticus

Quick Recap

Neurology System, Protocol 4/12.

1. Definition

Status epilepticus (SE) = a single seizure lasting >5 minutes, OR >=2 seizures without full return to baseline consciousness between them (the modern, revised operational definition — shorter than the older 30-minute threshold, reflecting that treatment should not wait for the historical cutoff).

Refractory SE (RSE): SE persisting despite adequate first-line benzodiazepine AND second-line ASM loading — occurs in 20-40% of SE presentations, typically after seizures have persisted 30-60+ minutes; carries significantly higher mortality/worse functional outcome.

Super-refractory SE (SRSE): SE that persists >=24h after onset of IV anesthetic treatment, OR recurs while anesthetics are being weaned — occurs in ~9% of SE patients.

2. Pathophysiology

As SE progresses over the first few hours, a critical receptor-level shift occurs: brain cells internalize inhibitory GABA receptors while externalizing excitatory AMPA/NMDA receptors — this explains both why benzodiazepine efficacy DECREASES the longer SE persists (a key rationale for acting fast rather than repeating benzodiazepine doses indefinitely) and why NMDA-antagonists like ketamine can offer benefit once GABA-agonist-only strategies fail.

3. Immediate Stabilization (ABCDE) — Step 1

Airway: positioning, oral suctioning, oral airway device; intubate if necessary. If intubation is required during RSE management, avoid paralytics or restrict to short-acting agents — paralysis masks ongoing convulsive movements and can hide persistent seizure activity from bedside observation (EEG becomes essential once paralyzed).

Breathing: monitor RR/SpO2 closely — respiratory depression is a major benzodiazepine/anesthetic risk.

Circulation: urgent IV access (preferably two lines); monitor HR/BP closely during benzodiazepine and subsequent drug administration.

Checklist:

4. Step 2: Terminate Seizures — First-Line Benzodiazepine

• Lorazepam 0.1 mg/kg (max 2mg... actually higher adult dosing per some protocols; pediatric reference max 4mg) IV slow push — preferred first-line given longer CNS duration of action vs other benzodiazepines
• Alternative: diazepam or midazolam 0.2mg/kg slow IV; IM midazolam is a validated, effective alternative when IV access is delayed (established by RAMPART trial-level evidence in the broader literature)
• Rectal diazepam or intranasal/buccal midazolam are options when no IV access is available
• Monitor closely for respiratory depression and hypotension
• If seizures persist ~5-10 minutes after benzodiazepine: proceed to Step 3 — do not simply repeat benzodiazepine doses indefinitely, given the declining GABA-receptor efficacy described in Section 2

5. Step 3: Second-Line ASM Loading ("Treat Resistant Seizure")

Choice among agents — no strong comparative evidence favors one over another; select per patient factors (renal/hepatic function, hemodynamic stability, allergy history):

• Fosphenytoin 20mg/kg phenytoin-equivalents IV, slow push over 5-10 min (preferred over phenytoin itself given fewer infusion-site/cardiac complications)
• Levetiracetam 60mg/kg (max 4500mg), infused at max rate 100mg/min — favorable side-effect profile, no need to check post-load level
• Valproic acid 30-35mg/kg (some protocols cite up to 40mg/kg), diluted, infused over ~20 min — caution: can cause profound hypotension
• Phenobarbital 20mg/kg, max infusion rate 50-70mg/min — respiratory depression/hypotension risk, especially combined with benzodiazepines; may be first choice in neonates/infants
• Lacosamide 400mg IV single dose over 5 min — check ECG for PR prolongation before use given cardiac arrhythmia risk

Post-load level monitoring (check 1 hour after IV load):

Underdosing increases the likelihood seizures persist — use full weight-based loading doses, not conservative estimates.

Maintenance after loading: continue the loaded ASM to prevent recurrence, titrated to therapeutic levels (phenytoin/valproate/phenobarbital) or standard maintenance dosing (levetiracetam 2-4g/day divided BID, renal-adjusted; lacosamide 200-400mg/day divided BID).

Accelerated/simultaneous approach (time-sensitive alternative): rather than sequential single-agent trials, some protocols start a second-line ASM (valproate or levetiracetam) AND a midazolam infusion simultaneously once ~30-45 minutes have elapsed, given how much time is lost with strict sequential dosing — "it is best to optimize levels of one drug before adding another" as a general principle, but do not let this slow definitive escalation once the clock is clearly running out.

6. Step 4: Refractory Status Epilepticus (RSE) Management

Once first-line benzodiazepine + second-line ASM load have failed (typically 30-60+ minutes of ongoing seizure activity), the patient has RSE — requires ICU admission, continuous anesthetic infusion, ventilatory support, and continuous EEG (ideally with video) monitoring.

Critical recognition: convulsive SE often evolves into NONCONVULSIVE RSE — electrical seizure activity dissociates from obvious motor expression; subtle signs include facial myoclonus, tonic eye deviation, or nystagmus. This requires EEG to diagnose and monitor — the absence of visible convulsions does NOT mean the seizure has stopped.

Anesthetic infusion comparison table:

Selection guidance (not rigorously evidence-based, more expert-pattern-based):

• Midazolam reasonable first-line if the goal is EEG seizure cessation
• Propofol most often used when midazolam fails, or when burst suppression (not just seizure cessation) is the target
• Pentobarbital most often reserved for SRSE rather than first-line RSE
• Ketamine as an add-on when GABA-agonist-only strategy is failing — some series show improved seizure control with 24+ hours of addition, notably WITHOUT significant adverse effects on ICP, CPP, or CBF
• Retrospective studies show no mortality difference between targeting seizure cessation vs burst suppression as the EEG endpoint

Choice of target (seizure cessation vs burst suppression) and choice of agent is NOT guided by rigorous comparative evidence — based on patient hemodynamic stability, seizure severity/duration, treatment goal, and local/institutional experience.

Propofol-related infusion syndrome (PRIS): real risk with high cumulative propofol doses often required for RSE — metabolic acidosis, hyperkalemia, rhabdomyolysis, renal failure, bradycardia, arrhythmia (including arrest). All patients on deep sedation require mechanical ventilation with meticulous VAP/nosocomial infection prevention attention.

Background ASM maintenance is essential during anesthetic infusion — if background AED levels are not maintained, seizures WILL recur when anesthetics are weaned. Continue/titrate phenytoin, levetiracetam, lacosamide, valproate, topiramate, etc. throughout and after anesthetic use.

7. Step 5: Super-Refractory Status Epilepticus (SRSE)

Occurs in ~9% of SE patients — SE persisting >=24h after IV anesthetic onset or recurring during anesthetic wean. Mortality/morbidity at this stage exceeds 50% in some pediatric series, though adult prognosis is more nuanced (Section 10).

Management: deepen/prolong sedation targeting burst suppression — propofol + ketamine in combination, or switch to pentobarbital infusion. If these fail, therapeutic hypothermia (31-35C, titrated to EEG response) is an option in resistant cases or where propofol/high-dose barbiturates are contraindicated — evidence base is limited (small case series), but the key practical advantage is rapid offset of metabolic suppression on rewarming, unlike pentobarbital which persists for days after infusion stops.

Other SRSE options: ketogenic diet induction (specialized feeding), electroconvulsive therapy, vagus nerve stimulation, neurosurgical resection for focal epileptic lesions.

Actively evaluate for rare/reversible causes in patients with no prior seizure history who develop SRSE — autoimmune/paraneoplastic encephalitis-associated SRSE responds significantly to immunotherapy (steroids, IVIG, plasmapheresis), making this an important, actionable diagnostic branch point rather than "just another refractory case."

8. Investigations

Glucose (immediate, reversible cause), electrolytes (Na, Ca, Mg), renal/hepatic function, ASM levels if applicable, toxicology screen, continuous EEG (mandatory for RSE/SRSE and for excluding nonconvulsive SE), head CT/MRI (structural cause, especially if focal onset or no prior seizure history), LP if infectious/autoimmune encephalitis suspected, autoimmune/paraneoplastic antibody panel if SRSE with no clear cause.

9. De-escalation / Weaning

Once EEG treatment goal achieved (seizure cessation and/or burst suppression), maintain infusion rate and EEG target for 24 hours before gradually weaning — do not wean prematurely just because seizures have stopped for a short period. Very gradual tapering is essential — recurrence is common and often nonconvulsive, detectable only by EEG. Remove the most toxic or most recently introduced agent first, ensuring long-term background ASMs are on board and at therapeutic levels before tapering begins. Complete avoidance of ALL epileptiform EEG activity (e.g., periodic discharges) may not be necessary unless clearly associated with persistent mental status change or evolving toward seizure.

10. Prognosis

~50% of ICU-treated RSE patients recover to baseline function; ~30% have new functional deficits. Mortality 10-20% in convulsive RSE, correlating with etiology. Importantly, SRSE does NOT necessarily carry a worse outcome than RSE — duration of refractoriness alone should not drive premature pessimism. Worse prognosis factors: older age, severely impaired consciousness, cryptogenic SRSE cause. Young patients with RSE/SRSE (even requiring a month+ of sedative therapy) can still have gratifying recoveries if ICU complications are avoided and the underlying cause is reversible (e.g., encephalitis) and treated successfully — an important point for sustaining aggressive care rather than premature withdrawal in young patients with a potentially reversible etiology.

Postanoxic SE (in comatose cardiac arrest survivors) is a special, more ominous case — especially with myoclonic jerking, it is one of the most consistent predictors of death/nonrecovery. Exception: SE with a preserved brainstem exam and EEG reactivity may still warrant more aggressive treatment. Postanoxic myoclonus/SE may transiently respond to valproate, clonazepam, or levetiracetam, but is usually refractory overall — aggressive escalation should generally be withheld pending explicit prognosis discussion with family in this specific postanoxic context (see Post-Cardiac Arrest Syndrome protocol).

11. Consultation Matrix

12. Monitoring Framework

Continuous EEG (mandatory for RSE/SRSE), continuous hemodynamic monitoring during anesthetic infusions, ASM level trending, temperature monitoring (esp. if hypothermia used for SRSE), watch for PRIS if high-dose propofol used, ventilator/VAP prevention monitoring.

13. Complications

Respiratory depression/failure, hypotension (benzodiazepine/anesthetic-related), PRIS, VAP/nosocomial infection during prolonged sedation, seizure recurrence on inadequate background ASM maintenance, aspiration. Prevention: careful anesthetic titration, background ASM maintenance, VAP bundle adherence, gradual (not abrupt) weaning. Rescue: agent switch (e.g., midazolam to propofol to pentobarbital), addition of ketamine, hypothermia for SRSE.

14. Escalation & De-escalation

Escalate: benzodiazepine failure at 5-10 min -> second-line ASM; second-line failure at 30-60 min -> anesthetic infusion (RSE); anesthetic failure at 24h -> deepen/combine/switch agents, consider hypothermia (SRSE).

De-escalate: per Section 9, only after 24h of sustained EEG goal, very gradual, background-ASM-protected wean.

15. Documentation & Medicolegal Checklist

16. Key Guidelines

Brophy GM, Bell R, Claassen J, et al. Guidelines for the management of status epilepticus. Neurocrit Care. 2012;17:3-23 (Neurocritical Care Society) — primary reference.

17. Landmark Evidence

Chiu WT, Campozano V, Schiefecker A, et al. Management of refractory status epilepticus: an international study (MORSE CODe) analysis. Neurology. 2022;99:e1191-e1201. Corry JJ, Dhar R, Murphy T, et al. Hypothermia for refractory status epilepticus. Neurocrit Care. 2008;9:189-197. Fisch U, Jünger AL, Baumann SM, et al. Association between induced burst suppression and clinical outcomes in RSE: 9-year cohort study. Neurology. 2023;100:e1955-e1966.

18. Controversies

Seizure cessation vs burst suppression as the EEG treatment target for RSE remains unresolved — retrospective data show no mortality difference, yet the choice significantly affects drug selection and depth of sedation, and practice varies by institution. Choice of first anesthetic agent (midazolam vs propofol vs pentobarbital vs ketamine) lacks rigorous comparative RCT evidence and is guided by pattern/experience rather than a validated algorithm. Hypothermia for SRSE rests on very limited case-series evidence. The clinical significance and treatment threshold for periodic EEG discharges that fall short of clear seizure activity remains genuinely debated.

19. References

1. Grover EH, Freeman WD. Status Epilepticus. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 54).
2. Brophy GM, Bell R, Claassen J, et al. Guidelines for the management of status epilepticus. Neurocrit Care. 2012;17:3-23.
3. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40:120-122.
4. Chiu WT, Campozano V, Schiefecker A, et al. MORSE CODe analysis. Neurology. 2022;99:e1191-e1201.
5. Corry JJ, Dhar R, Murphy T, et al. Hypothermia for refractory status epilepticus. Neurocrit Care. 2008;9:189-197.
6. Fisch U, Jünger AL, Baumann SM, et al. Burst suppression and clinical outcomes in RSE. Neurology. 2023;100:e1955-e1966.
7. Udani S. Status Epilepticus. ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020 (Ch. 35) — stepwise algorithmic framework adapted here.